Fibrocell Science (NASDAQ:FCSC) Downgraded by Zacks Investment Research

Share on StockTwits

Zacks Investment Research downgraded shares of Fibrocell Science (NASDAQ:FCSC) from a hold rating to a sell rating in a report published on Tuesday, reports.

According to Zacks, “Fibrocell Science, Inc. is an autologous cell and gene therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs. Fibrocell’s most advanced drug candidate, azficel-T, uses its FDA-approved proprietary autologous fibroblast technology and is in a Phase II clinical trial for the treatment of chronic dysphonia resulting from vocal cord scarring or atrophy. In collaboration with Intrexon Corporation, a leader in synthetic biology, Fibrocell is also developing gene therapies for orphan skin diseases using gene-modified autologous fibroblasts. The Company’s lead orphan gene-therapy drug candidate, FCX-007, is in late stage pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa. Fibrocell is also in pre-clinical development of FCX-013, its second gene-therapy drug candidate, for the treatment of linear scleroderma. “

FCSC has been the subject of a number of other reports. ValuEngine raised shares of Zumiez from a sell rating to a hold rating in a report on Saturday, June 22nd. HC Wainwright upped their price objective on shares of Largo Resources from C$5.10 to C$5.20 in a research note on Thursday, March 28th.

Shares of NASDAQ FCSC opened at $1.84 on Tuesday. Fibrocell Science has a twelve month low of $1.45 and a twelve month high of $3.28. The company has a quick ratio of 3.59, a current ratio of 3.59 and a debt-to-equity ratio of 0.85. The firm has a market cap of $18.05 million, a P/E ratio of -1.27 and a beta of 1.63. The firm has a 50-day simple moving average of $1.91.

Fibrocell Science (NASDAQ:FCSC) last issued its quarterly earnings results on Wednesday, May 15th. The company reported ($0.40) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.33) by ($0.07). On average, sell-side analysts anticipate that Fibrocell Science will post -1.31 EPS for the current year.

A hedge fund recently bought a new stake in Fibrocell Science stock. Apis Capital Advisors LLC acquired a new stake in shares of Fibrocell Science Inc (NASDAQ:FCSC) in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 25,000 shares of the company’s stock, valued at approximately $48,000. Apis Capital Advisors LLC owned approximately 0.26% of Fibrocell Science at the end of the most recent quarter. 28.04% of the stock is owned by institutional investors and hedge funds.

About Fibrocell Science

Fibrocell Science, Inc, an autologous cell and gene therapy company, focuses on discovering and developing therapies for diseases affecting the skin and connective tissues in the United States. The company's gene therapy product candidates include FCX-007 that is in Phase I/II clinical trials to treat recessive dystrophic epidermolysis bullosa; FCX-013, a gene therapy for localized scleroderma; and gene-therapy program that is in research phase to arthritis and related conditions.

Featured Story: What is the Fibonacci sequence?

Get a free copy of the Zacks research report on Fibrocell Science (FCSC)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Fibrocell Science Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell Science and related companies with's FREE daily email newsletter.